A woman holds her malnourished child at a therapeutic feeding center at al-Sabyeen hospital in Sanaa May 28, 2012. REUTERS/Mohamed al-Sayaghi

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

A woman walks past silkscreen prints of Britain's Queen Elizabeth by Andy Warhol during a press view at the National Portrait Gallery in London May 16, 2012. REUTERS/Stefan Wermuth (BRITAIN - Tags: ENTERTAINMENT SOCIETY ROYALS)

Long live the Queen

Britain gets ready to celebrate Queen Elizabeth's Diamond Jubilee.  Slideshow 

Photo

The autistic mind

Scenes from a home with two autistic children.  Slideshow 

Japan develops brain and eye pills for gaming fans

Related Topics

A video game enthusiast plays a game on the HP Blackbird 002 system at the HP booth at the E for All video game expo in Los Angeles, California October 19, 2007. REUTERS/Fred Prouser

A video game enthusiast plays a game on the HP Blackbird 002 system at the HP booth at the E for All video game expo in Los Angeles, California October 19, 2007.

Credit: Reuters/Fred Prouser

TOKYO | Wed Apr 9, 2008 3:12am EDT

TOKYO (Reuters) - Gaming addicts with sore eyes and tired brains may be able to perk up with "Game Suppli", a new Japanese supplement developed specifically for the country's thousands of fanatic players.

"We concentrated on developing a supplement for those who love games," reads the advert for the pills on www.cybergadget.co.jp, a Web site that sells a range of accessories for video game fans.

Maker Kyowa-Yakuhin produces two different supplements for the "Game Suppli" range: blueberry tablets that are meant to be good for the eyes, and transparent capsules containing Docosahexaenoic acid, or DHA, a fatty acid that supposedly enhances concentration.

Japan's convenience stores are stacked with drinks and capsules claiming various health and beauty benefits, sometimes without any scientific evidence.

(Reporting by Sophie Hardach)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.